Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Sumitomo Dainippon Pharma Co Ltd    4506   JP3495000006

SUMITOMO DAINIPPON PHARMA CO LTD (4506)
My previous session
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2019 468 B
EBIT 2019 -
Net income 2019 33 622 M
Finance 2019 133 B
Yield 2019 0,69%
Sales 2020 452 B
EBIT 2020 -
Net income 2020 34 817 M
Finance 2020 159 B
Yield 2020 0,69%
P/E ratio 2019 32,30
P/E ratio 2020 34,98
EV / Sales2019 2,16x
EV / Sales2020 2,18x
Capitalization 1 146 B
More Financials
Company
Sumitomo Dainippon Pharma Co., Ltd. engages in manufacturing, sale, import and export of pharmaceuticals products.It operates through the Pharmaceutical Business and Other Business segments.The Pharmaceutical Business segment handles the creation of new pharmaceutical products.The Other Business... 
Sector
Pharmaceuticals
Calendar
01/31Earnings Release
More about the company
Surperformance© ratings of Sumitomo Dainippon Pharma
Trading Rating : Investor Rating :
More Ratings
Latest news on SUMITOMO DAINIPPON PHARMA
11/05SUMITOMO DAINIPPON PHARMA : Sumitomo Dainippon Pharma announces the Clinical Dat..
AQ
10/18SUMITOMO DAINIPPON PHARMA : to Invest in and Start Joint Research and Developmen..
AQ
10/18Poxel Announces Third Quarter and Nine Months 2018 Financial Update
AQ
10/10Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
AQ
09/26SUMITOMO DAINIPPON PHARMA CO LTD : Ex-dividend day for interim dividend
FA
09/21SUMITOMO DAINIPPON PHARMA : Contributes to the 2018 Hokkaido Eastern Iburi Earth..
AQ
09/21Poxel Reports Financial Results for the First Half 2018 and Provides Corporat..
AQ
09/12Sumitomo Dainippon Pharma Co., Ltd. - Results of Phase 3 Studies Evaluating P..
AQ
09/04SUMITOMO DAINIPPON PHARMA : Sumitomo Dainippon Pharma announces personnel change..
AQ
08/29Poxel Announces Completion of Patient Enrollment for the TIMES 3 Trial in the..
AQ
More news
Sector news : Pharmaceuticals - NEC
11:11aPfizer loses Lyrica drug patent fight in UK Supreme Court
RE
09:39aSouth Korea regulator says Samsung BioLogics intentionally breached accountin..
RE
08:48aBAYER : Weedkiller Lawsuits Mount At Bayer
DJ
08:15aSHIRE : Rule 2.9 Announcement
DJ
08:02aMERCK : 3Q Net Profit Fell; Lifts 2018 Organic Sales Growth View -- Update
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
08/29$Tokyo Stock Exchange Pharmaceutical Co Ltd Sumitomo Dainippon Pharma Co Ltd.. 
07/27MarketLine - Sumitomo Dainippon Pharma Co., Ltd. - Mergers Acquisitions (MA),.. 
07/16WATCH: Hiroshi Nomura rescued 20 people from torrential flooding in his home ..
14
02/16BRIEF-Intercept Pharma Says Sumitomo Dainippon Pharma Enters Into Amendment T.. 
2017Poxel and Sumitomo Dainippon Pharma Announce Initiation of Phase 3 Program fo.. 
More tweets
Qtime:24
News from SeekingAlpha
07/18ADHD CHECK-UP : Which Future Medications Have The Greatest Potential? 
2017Why Is Tension Rising In The South China Sea? 
Chart SUMITOMO DAINIPPON PHARMA CO LTD
Duration : Period :
Sumitomo Dainippon Pharma Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUMITOMO DAINIPPON PHARMA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 1 835  JPY
Spread / Average Target -36%
EPS Revisions
Managers
NameTitle
Hiroshi Nomura President & Representative Director
Masayo Tada Chairman
Yoshiharu Ikeda General Manager-Research Technology
Nobuyuki Hara Director, Executive Officer & GM-Development
Hitoshi Odagiri Director, Managing Executive Officer & GM-Sales
Sector and Competitors
1st jan.Capitalization (M$)
SUMITOMO DAINIPPON PHARMA CO LTD70.88%10 062
--.--%0
--.--%0